Tier 2 — strong

Oncometabolites in Cancer Metabolism: Mechanistic Insights and Biomarker Potential — A Narrative Review

Khatun MM, Sarker MA, Podder MK, Biswas MS, Hasan MM, Tamannaa Z, Hossain MN, Badhon RS, Akter MA
Health Science Reports 2026 9(8):e73070

Bibliography

PubMed
PMID 42621358
PubMed Central
PMC13487703
DOI
10.1002/hsr2.73070
Funding
The authors report they have nothing to disclose.
Competing interests
The authors declare no financial or other conflicts of interest.

Study snapshot

DesignNarrative review of the cancer-metabolism literature (PubMed and Google Scholar search through 2025)
ModelNot applicable — literature review, no experimental model
SampleNot applicable — literature review
InterventionNot applicable — no intervention; reviews how oncometabolites (2-hydroxyglutarate, succinate, fumarate) that arise from mutated metabolic enzymes act as competitive inhibitors of alpha-ketoglutarate-dependent dioxygenases, including the TET and JmjC enzyme families and prolyl hydroxylases
DurationNot applicable
EndpointsMechanistic synthesis of oncometabolite biology (IDH1/2, SDH, FH mutations); Biomarker potential of oncometabolites for diagnosis, prognosis, and monitoring

What the study showed, in plain terms

This 2026 narrative review is not a study of Ca-AKG. It is included in the Data Center because it explains an important piece of context for the honest evidence conversation about Ca-AKG and cancer: several molecules that drive certain cancers — 2-hydroxyglutarate, succinate, and fumarate — work by blocking the same family of AKG-dependent enzymes that AKG itself fuels normally.

In cancers driven by mutations in IDH1, IDH2, SDH, or FH, these "oncometabolites" accumulate and act as competitive inhibitors of AKG-dependent dioxygenases, disrupting normal DNA and histone demethylation and pushing cells towards a cancer-permissive state. The review discusses how measuring these oncometabolites is being explored as a cancer biomarker strategy.

The honest read for a Ca-AKG reader: this paper does not test, support, or refute the idea that taking Ca-AKG affects cancer risk in either direction. It explains why the AKG-dependent enzyme family matters in cancer biology generally — which is exactly why any claim that supplemental AKG straightforwardly "fights cancer" or is guaranteed safe in a personal or family cancer history deserves real scrutiny rather than assumption in either direction.

Key findings

  • Oncometabolites competitively inhibit AKG-dependent enzymes: (R)-2-hydroxyglutarate (from mutant IDH1/2), succinate (from SDH loss), and fumarate (from FH loss) all structurally resemble AKG closely enough to block the active site of AKG-dependent dioxygenases, including TET and JmjC demethylases and prolyl hydroxylases.
  • This drives epigenetic and hypoxia-pathway dysregulation: blocking these enzymes causes DNA and histone hypermethylation, pseudohypoxic signalling, and altered redox balance — mechanisms with established roles in tumour biology.
  • Biomarker potential is an active research direction: 2-hydroxyglutarate and related metabolic signatures are detectable by magnetic resonance spectroscopy and mass spectrometry-based metabolomics, with diagnostic, prognostic, and monitoring applications under investigation.

What this study can and cannot tell us

Not a study of supplemental AKG. This is the single most important limitation for Biohack Blueprint readers: the review covers the biology of oncometabolites that inhibit AKG-dependent enzymes in specific gene-mutant cancers. It does not measure, model, or discuss the effect of exogenous Ca-AKG supplementation on cancer risk or progression, in either direction.

Narrative, not systematic. The review describes a focused but non-systematic PubMed and Google Scholar search rather than a pre-registered systematic methodology, so selection of the underlying primary literature was not independently, formally screened.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology